1. Home
  2. OTIS vs RPRX Comparison

OTIS vs RPRX Comparison

Compare OTIS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Otis Worldwide Corporation

OTIS

Otis Worldwide Corporation

HOLD

Current Price

$66.11

Market Cap

27.5B

Sector

Technology

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

SELL

Current Price

$56.47

Market Cap

25.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OTIS
RPRX
Founded
1853
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.5B
25.9B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
OTIS
RPRX
Price
$66.11
$56.47
Analyst Decision
Buy
Buy
Analyst Count
14
8
Target Price
★ $86.54
$65.13
AVG Volume (30 Days)
★ 4.3M
2.8M
Earning Date
10-28-2026
11-04-2026
Dividend Yield
★ 2.67%
1.66%
EPS Growth
N/A
★ N/A
EPS
★ 1.99
0.71
Revenue
N/A
★ $2,378,193,000.00
Revenue This Year
$6.04
$47.32
Revenue Next Year
$4.64
$8.70
P/E Ratio
★ $33.11
$79.82
Revenue Growth
N/A
★ 5.06
52 Week Low
$63.59
$35.23
52 Week High
$94.20
$64.38

Technical Indicators

Market Signals
Indicator
OTIS
RPRX
Relative Strength Index (RSI) 41.22 33.26
Support Level N/A $56.36
Resistance Level $75.17 $56.50
Average True Range (ATR) 1.56 1.05
MACD -0.10 -0.23
Stochastic Oscillator 38.12 13.86

Price Performance

Historical Comparison
OTIS
RPRX

About OTIS Otis Worldwide Corporation

Otis is the largest global elevator and escalator supplier by revenue with around 18% global market share. In 1854 Otis' founder and namesake Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed. The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15- to 20-year useful life of an elevator. As the largest global OEM, Otis has amassed an installed base under service that exceeds 2 million elevators. Its business model is similar to that of its closest competitors Kone, Schindler, and TK Elevator.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: